Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rexer

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Der Urologe. Ausg. A|May 12, 2012
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)]H Rexer
Der Urologe. Ausg. A|February 15, 2012
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)]H Rexer
Der Urologe. Ausg. A|May 18, 2011
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer]H Rexer
Der Urologe. Ausg. A|October 7, 2011
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)]H Rexer
Der Urologe. Ausg. A|December 14, 2011
[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)]H Rexer
Der Urologe. Ausg. A|January 22, 2011
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO)]H Rexer
Der Urologe. Ausg. A|February 12, 2011
[AUO-study AB34/09: an open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PURO]H Rexer
Der Urologe. Ausg. A|May 14, 2014
[Study on the therapy of nonmuscle-invasive bladder cancer: treatment of nonmuscle-invasive high-grade urothelial cancer of the bladder with the standard number and dosage of intravesical BCG instillations versus a reduced number of intravesical BCG instillations in the standard dosage: a randomized phase 3 study of the European Association of Urology Research Foundation (NIMBUS - AB 37/10 of the AUO)]H Rexer
Der Urologe. Ausg. A|April 15, 2004
[New testis tumor study AH 09/03/XX--darbepoetin activated]H Rexer
Der Urologe. Ausg. A|November 5, 2004
[Randomized phase III study on nonseminomatous testicular tumor]H Rexer
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Der Urologe. Ausg. A|May 12, 2012
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)]H Rexer
Der Urologe. Ausg. A|February 15, 2012
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)]H Rexer
Der Urologe. Ausg. A|May 18, 2011
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer]H Rexer
Der Urologe. Ausg. A|October 7, 2011
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)]H Rexer
Der Urologe. Ausg. A|December 14, 2011
[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427 - AB 39/11 of the Working Group Urological Oncology)]H Rexer
Der Urologe. Ausg. A|January 22, 2011
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO)]H Rexer
Der Urologe. Ausg. A|February 12, 2011
[AUO-study AB34/09: an open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PURO]H Rexer
Der Urologe. Ausg. A|May 14, 2014
[Study on the therapy of nonmuscle-invasive bladder cancer: treatment of nonmuscle-invasive high-grade urothelial cancer of the bladder with the standard number and dosage of intravesical BCG instillations versus a reduced number of intravesical BCG instillations in the standard dosage: a randomized phase 3 study of the European Association of Urology Research Foundation (NIMBUS - AB 37/10 of the AUO)]H Rexer
Der Urologe. Ausg. A|April 15, 2004
[New testis tumor study AH 09/03/XX--darbepoetin activated]H Rexer
Der Urologe. Ausg. A|November 5, 2004
[Randomized phase III study on nonseminomatous testicular tumor]H Rexer
Pageof 11